Home Alzheimer’s Disease

Alzheimer’s Disease

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Former CMO and Execute VP of ASCO on Molecular Profiling in GI Cancer and Health Inequity

Richard Schilsky, MD, touched on the research driving ASCO to award “Advance of the Year” to molecular profiling in gastrointestinal cancers, and what the...

First-Line Nivolumab/Ipilimumab and 2 Chemo Cycles Provide Superior OS Vs Chemo Alone in Advanced NSCLC

Nivolumab (Opdivo) plus ipilimumab (Yervoy) and 2 cycles of chemotherapy provided superior overall survival (OS) results compared with chemotherapy alone as well as a...

Study Identifies Oncology Health Professionals’ Conflicting Perceptions of Telehealth

A study published in JAMA Network Open highlighted the conflicting opinions of oncologic health care professionals regarding telehealth and gave insight into potential barriers...

FDA Grants Priority Review to sNDA for Ruxolitinib to Treat Steroid-Refractory cGVHD

The FDA has accepted and granted priority review to a supplemental new drug application (sNDA) for the first-in-class JAK1/JAK2 inhibitor ruxolitinib (Jakafi) for the...

Salma Jabbour, MD, on AEs Observed With Pembrolizumab Plus Concurrent Chemoradiotherapy in Stage III NSCLC

Results from the ongoing KEYNOTE-799 study (NCT03631784) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) Singapore demonstrated promising safety and efficacy...

FDA Grants Fast Track Designation to GEN-1 Immunotherapy for Treatment of Advanced Ovarian Cancer

The FDA granted fast track designation to a DNA-mediated interleukin-12 (IL-12) immunotherapy, GEN-1, to treat patients with advanced ovarian cancer, according to a press...

FDA Approves Cemiplimab as First-Line Treatment for Advanced, High PD-L1 NSCLC

The FDA has approved the PD-1 inhibitor cemiplimab-rwlc (Libtayo) as a first-line treatment option for patients with locally advanced or metastatic non–small cell lung...

AstraZeneca Withdraws Durvalumab Indication for Previously Treated Locally Advanced or Metastatic Bladder Cancer

AstraZeneca announced it has voluntarily withdrawn the indication for durvalumab (Imfinzi) in previously treated adult patients with locally advanced or metastatic bladder cancer in...

Adjuvant Pazopanib Does Not Improve Overall Survival for Patients With Locally Advanced RCC

Adjuvant pazopanib (Votrient) treatment did not positively impact overall survival (OS) rates following resection in patients with locally advanced renal cell carcinoma (RCC), according...

Michael Szarek, PhD, on the Rationale Behind Conducting a Q-TWiST Analysis of the Phase 3 TIVO-3 Study

An analysis of tivozanib versus sorafenib in patients with advanced renal cell carcinoma (RCC) included in the phase 3 TIVO-3 study revealed that, as...

Most Read

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in...